---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-001657"
form_type: "8-K"
ticker: "AGEN"
cik: "0001098972"
company_name: "AGENUS INC"
filed_at: "2023-03-14T23:59:59+00:00"
generated_at: "2026-06-18T02:49:47.588734+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Agenus Q4 net loss $74M; botensilimab shows 23% ORR in MSS CRC, 50% in NSCLC

## Summary
- Q4 2022 revenue $28.4M, net loss $74.1M ($0.24/sh); FY22 revenue $98M, net loss $230.7M ($0.78/sh).
- Cash & short-term investments $193M at Dec 31, 2022, down from $307M a year earlier.
- Botensilimab/balstilimab combo: 23% ORR in MSS CRC (70 evaluable), 50% ORR in PD-(L)1 refractory NSCLC (8 evaluable).
- Phase 3 confirmatory trial in MSS CRC expected in 2023; randomized Phase 2 ACTIVATE studies ongoing.
- Potential future milestones from collaborations up to $2.7B; nine new partner trials launched in 2022.

## SEC filing metadata
- accession: 0001171843-23-001657
- form_type: 8-K
- ticker: AGEN
- cik: 0001098972
- company_name: AGENUS INC
- filed_at: 2023-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1098972/000117184323001657/0001171843-23-001657-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1098972/000117184323001657/f8k_031423.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-001657
- JSON: https://secwatch.observer/filing/0001171843-23-001657.json
- Plain text: https://secwatch.observer/filing/0001171843-23-001657.txt

## Key facts
- Earnings Releases
  AGENUS INC reported financial results for quarter and year ended December 31, 2022.
  - Period: quarter and year ended December 31, 2022
  - Result: reported results
  source text: On March 14, 2023, Agenus Inc. announced its financial results for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1098972/000117184323001657/0001171843-23-001657-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.